Pfizer Inc. and Astellas are collaborating to provide grant support for continuing professional education in bladder cancer.
The recent update of the NCCN Bladder Guidelines for First-Line Systemic Therapy for Locally Advanced of Metastatic Disease represents a substantial shift in the standard-of-care for patients (ref. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Bladder Cancer Version 4.2024 — May 9, 2024). It is important for oncologists, nurses and all members of the multi-disciplinary care team to be educated on these practice-changing updates and how to incorporate them safely and effectively for appropriate patients.
This competitive grant program seeks to support independent medical education activities that will increase knowledge of the new Guideline-based treatment recommendations and how that may shift the emerging treatment landscape in earlier lines of therapy, including muscle invasive bladder cancer (MIBC).
The intended learner audience can include medical oncologists (both in the community and academic settings), Advanced Practitioners (PA/NPs), urologists, nurses, other healthcare professionals on the multidisciplinary care team responsible for the treatment decisions for patients with urothelial cancer, and/or patients and caregivers.
Grant Application due date: July 19, 2024
The following types of organizations may apply: medical, nursing, allied health, and/or pharmacy professional schools; healthcare institutions (both large and small); professional organizations/medical societies; medical education companies; and other entities with a mission related to healthcare professional education and/or healthcare improvement.
Individual projects requesting up to $250,000 will be considered although smaller, focused projects with lower budgets will be preferred. Projects covering multiple activities over time may request up to $500,000. Funding will be allocated for 1-2 larger projects with the majority of the total available budget going toward multiple smaller projects (e.g. $50,000 - $80,000.) The estimated total available budget related to this RFP is $1,800,000 USD. Award amounts include direct costs, institutional overhead costs (28% maximum), and indirect costs.